Amazon cover image
Image from Amazon.com

Anticoagulants, antiplatelets, and thrombolytics / edited by Shaker A. Mousa.

Contributor(s): Mousa, Shaker AMaterial type: TextTextSeries: Springer protocols (Series) | Methods in molecular biology (Clifton, N.J.) ; v. 663.Publication details: New York, N.Y. : Humana Press, ©2010. Edition: 2nd edDescription: 1 online resource (xi, 316 pages) : illustrationsContent type: text Media type: computer Carrier type: online resourceISBN: 9781607618034; 1607618036Subject(s): Anticoagulants (Medicine) | Blood platelets | Thrombolytic therapy | Fibrinolytic agents | Therapeutics | Glycosaminoglycans | Hematologic Agents | Blood Platelet Disorders | Fibrin Modulating Agents | Cardiovascular Agents | Investigative Techniques | Hematologic Diseases | Therapeutic Uses | Polysaccharides | Analytical, Diagnostic and Therapeutic Techniques and Equipment | Molecular Mechanisms of Pharmacological Action | Anticoagulants | Platelet Aggregation Inhibitors | Fibrinolytic Agents | Thrombocytopenia | Methods | Drug Therapy | Heparin | Thrombolytic Therapy | Carbohydrates | Pharmacologic Actions | Hemic and Lymphatic Diseases | Chemical Actions and Uses | Disease | Chemicals and Drugs | Anticoagulants (Medicine) | Blood platelets | Fibrinolytic agents | Thrombolytic therapy | geneeskunde | medicine | biomedische wetenschappen | biomedicine | cardiologie | cardiology | Medicine (General) | Geneeskunde (algemeen)Genre/Form: Electronic books. Additional physical formats: Print version:: Anticoagulants, antiplatelets, and thrombolytics.DDC classification: 615/.718 LOC classification: RM340 | .A566 2010NLM classification: QZ 170Online resources: Click here to access online
Contents:
In vitro methods of evaluating antithrombotics and thrombolytics / S.A. Mousa -- In vivo models for the evaluation of antithrombotics and thrombolytics / S.A. Mousa -- Heparin and low-molecular weight heparins in thrombosis and beyond / S.A. Mousa -- Laboratory methods and management of patients with heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Novel anticoagulant therapy: Principle and practice / S.A. Mousa -- Oral direct factor xa inhibitors, with special emphasis on rivaroxaban / S.A. Mousa -- Antiplatelet therapies: Drug interactions in the management of vascular disorders / S.A. Mousa -- Prasugrel: A novel platelet adp p2y(12) receptor antagonist / S.A. Mousa, W.P. Jeske and J. Fareed -- Antithrombotic effects of naturally derived products on coagulation and platelet function / S.A. Mousa -- Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis / A. Amirkhosravi [and others] -- Adhesion molecules: Potential therapeutic and diagnostic implications / S.A. Mousa -- Pharmacogenomics in thrombosis / S.A. Mousa -- Diagnosis and management of sickle cell disorders / S.A. Mousa and M.H. Qari.
Summary: During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular Biology series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Collection Call number Status Date due Barcode Item holds
eBook eBook e-Library

Electronic Book@IST

EBook Available
Total holds: 0

Includes bibliographical references and index.

In vitro methods of evaluating antithrombotics and thrombolytics / S.A. Mousa -- In vivo models for the evaluation of antithrombotics and thrombolytics / S.A. Mousa -- Heparin and low-molecular weight heparins in thrombosis and beyond / S.A. Mousa -- Laboratory methods and management of patients with heparin-induced thrombocytopenia / M. Prechel, W.P. Jeske and J.M. Walenga -- Novel anticoagulant therapy: Principle and practice / S.A. Mousa -- Oral direct factor xa inhibitors, with special emphasis on rivaroxaban / S.A. Mousa -- Antiplatelet therapies: Drug interactions in the management of vascular disorders / S.A. Mousa -- Prasugrel: A novel platelet adp p2y(12) receptor antagonist / S.A. Mousa, W.P. Jeske and J. Fareed -- Antithrombotic effects of naturally derived products on coagulation and platelet function / S.A. Mousa -- Assessment of anti-metastatic effects of anticoagulant and antiplatelet agents using animal models of experimental lung metastasis / A. Amirkhosravi [and others] -- Adhesion molecules: Potential therapeutic and diagnostic implications / S.A. Mousa -- Pharmacogenomics in thrombosis / S.A. Mousa -- Diagnosis and management of sickle cell disorders / S.A. Mousa and M.H. Qari.

During the past decade, remarkable progress has been made in the development of newer drugs to prevent and treat thromboembolic disorders, such as oral direct anti-Xa and anti-IIa antagonists, as well as oral antiplatelet ADP antagonists with rapid onset and offset. In addition, there has been concentrated effort aimed at identifying novel uses of traditional antithrombotic drugs, such as aspirin, heparin, and oral anticoagulants, as well as combinations of agents, such as more than one antiplatelet, antiplatelet with anticoagulant, antiplatelet with or without thrombolytic. Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition provides updates on various strategies in thrombosis, experimental models, and clinical and recent advances in the discovery and development of novel antithrombotics. As a volume in the highly successful Methods in Molecular Biology series, this collection provides the kind of detailed description and implementation advice that is crucial for getting optimal results. Easy to use and up to date, Anticoagulants, Antiplatelets, and Thrombolytics, Second Edition is an ideal guide for researchers aiming for the future of this vital field, focusing on the prevention of thromboembolic disorders and the protection of the vascular endothelium.

English.

Powered by Koha